Evidence map›Paper›PMID 28458036›Full record

ArticleVirology2017

A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.

Lydia R Meador, Sarah A Kessans, Jacquelyn Kilbourne, Karen V Kibler, Giuseppe Pantaleo, Mariano Esteban Roderiguez, Joseph N Blattman, Bertram L Jacobs, Tsafrir S Mor

Erratum issuedAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Lydia R MeadorIra A. Fulton School of Engineering, Arizona State University, Tempe, AZ, USA; Center for Infectious Diseases and Vaccinology, The Biodesign Institute, Arizona State University, Tempe, AZ, USA.
Sarah A KessansCenter for Infectious Diseases and Vaccinology, The Biodesign Institute, Arizona State University, Tempe, AZ, USA; School of Life Sciences, Arizona State University, Tempe, AZ, USA.
Jacquelyn KilbourneCenter for Infectious Diseases and Vaccinology, The Biodesign Institute, Arizona State University, Tempe, AZ, USA.
Karen V KiblerCenter for Infectious Diseases and Vaccinology, The Biodesign Institute, Arizona State University, Tempe, AZ, USA.
Giuseppe PantaleoDivision of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland; Swiss Vaccine Research Institute, Lausanne, Switzerland.
Mariano Esteban RoderiguezDepartment of Molecular and Cellular Biology, Centro Nacional de Biotecnologia - CSIC, Madrid, Spain.
Joseph N BlattmanCenter for Infectious Diseases and Vaccinology, The Biodesign Institute, Arizona State University, Tempe, AZ, USA; School of Life Sciences, Arizona State University, Tempe, AZ, USA.
Bertram L JacobsCenter for Infectious Diseases and Vaccinology, The Biodesign Institute, Arizona State University, Tempe, AZ, USA; School of Life Sciences, Arizona State University, Tempe, AZ, USA. Electronic address: bjacobs@asu.edu.
Tsafrir S MorCenter for Infectious Diseases and Vaccinology, The Biodesign Institute, Arizona State University, Tempe, AZ, USA; School of Life Sciences, Arizona State University, Tempe, AZ, USA. Electronic address: tsafrir.mor@asu.edu.

Funding

Production CoreU19AI062150 · NIAID · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI ARNTZEN, CHARLES JOEL · 2004 to 2008
$7.2M
Monkeypox virus, Interferon, and NecroptosisR01AI095394 · NIAID · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI JACOBS, BERTRAM L. · 2012 to 2024
$4.9M
NIAID NIH HHS R01 AI095394NIAID NIH HHS U19 AI062150
6 · The paper itself

Abstract

Showing modest efficacy, the RV144 HIV-1 vaccine clinical trial utilized a non-replicating canarypox viral vector and a soluble gp120 protein boost. Here we built upon the RV144 strategy by developing a novel combination of a replicating, but highly-attenuated Vaccinia virus vector, NYVAC-KC, and plant-produced HIV-1 virus-like particles (VLPs). Both components contained the full-length Gag and a membrane anchored truncated gp41 presenting the membrane proximal external region with its conserved broadly neutralizing epitopes in the pre-fusion conformation. We tested different prime/boost combinations of these components in mice and showed that the group primed with NYVAC-KC and boosted with both the viral vectors and plant-produced VLPs have the most robust Gag-specific CD8 T cell responses, at 12.7% of CD8 T cells expressing IFN-γ in response to stimulation with five Gag epitopes. The same immunization group elicited the best systemic and mucosal antibody responses to Gag and dgp41 with a bias towards IgG1.

Indexed as

AIDS VaccinesAnimalsAntibodies, NeutralizingAntibody FormationFemalegag Gene Products, Human Immunodeficiency VirusGenetic VectorsHIV-1HIV AntibodiesHIV Envelope Protein gp41HIV InfectionsHumansImmunizationImmunization, SecondaryMiceMice, Inbred C57BLAIDS VaccinesAntibodies, Neutralizinggag Gene Products, Human Immunodeficiency VirusHIV AntibodiesHIV Envelope Protein gp41Vaccines, Virus-Like ParticleElectron microscopyHIV-1Live vector vaccinesPrime/boostSubunit vaccinesTobacco mosaic virusVaccinia virusVirus-like particles

Identifiers

PMID28458036
PMCPMC5529300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.